MDA-MB-361Homo sapiens (Human)Cancer cell line
Also known as: MDA-MB 361, MDA MB 361, MDA-MB361, MDAMB361, MDA-361, MDA361, MB361, MD Anderson-Metastatic Breast-361
Quick Overview
Human breast cancer cell line with chromosomal abnormalities and potential for research in cancer genetics.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
Database ID | CVCL_0620 |
---|---|
Species | Homo sapiens (Human) |
Tissue Source | Brain[UBERON:UBERON_0000955] |
Donor Information
Age | 40 |
---|---|
Age Category | Adult |
Sex | Female |
Race | caucasian |
Subtype Features | luminal ER+, HER2+ |
Disease Information
Disease | Breast adenocarcinoma |
---|---|
Lineage | Breast |
Subtype | Invasive Breast Carcinoma |
OncoTree Code | BRCA |
DepMap Information
Source Type | ATCC |
---|---|
Source ID | ACH-000934_source |
Known Sequence Variations
Type | Gene/Protein | Description | Zygosity | Note | Source |
---|---|---|---|---|---|
MutationSimple | BRAF | p.Val600Glu (c.1799T>A) | Unspecified | - | PubMed=26214590 |
MutationSimple | BRCA2 | p.Asn1657Ser (c.4970A>G) | Heterozygous | - | from parent cell line MDA-MB-361 |
MutationSimple | CDKN2A | p.Met52Ile (c.156G>C) (p.Asp67His, c.199G>C) | Homozygous | - | from parent cell line MDA-MB-361 |
MutationSimple | CDKN2A | p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T) | Homozygous | - | from parent cell line A-375 |
MutationSimple | PIK3CA | p.Glu545Lys (c.1633G>A) | Heterozygous | - | from parent cell line MCF-7 |
MutationSimple | PIK3CA | p.Lys567Arg (c.1700A>G) | Heterozygous | - | from parent cell line MDA-MB-361 |
MutationSimple | TP53 | p.Glu56Ter (c.166G>T) | Homozygous | - | from parent cell line MDA-MB-361 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis.
Bedford M.T., Shi X.-B., Li W., Barton M.C., Dent S.Y.R., Kraus W.L.
Genome Res. 28:159-170(2018).
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
Lakhani S.R.
Breast Cancer Res. Treat. 167:289-301(2018).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
Cell lines from human breast.";
Leibovitz A.
(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York; USA (1994).
Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization.
Cailleau R.M., Olive M., Cruciger Q.V.J.
In Vitro 14:911-915(1978).
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
Fogh J., Wright W.C., Loveless J.D.
J. Natl. Cancer Inst. 58:209-214(1977).
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
Wright W.C., Daniels W.P., Fogh J.
J. Natl. Cancer Inst. 66:239-247(1981).
Cytogenetic analysis on eight human breast tumor cell lines: high frequencies of 1q, 11q and HeLa-like marker chromosomes.
Satya-Prakash K.L., Pathak S., Hsu T.-C., Olive M., Cailleau R.M.
Cancer Genet. Cytogenet. 3:61-73(1981).
Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.
Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.
Oncogene 16:2865-2878(1998).
Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping.
Isola J.J., Larsson C.
Genes Chromosomes Cancer 28:308-317(2000).
Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.
Gooden G.C., Ethier S.P., Kallioniemi A.H., Kallioniemi O.-P.
Cancer Res. 60:4519-4525(2000).
Molecular cytogenetic analysis of breast cancer cell lines.";
Courtay-Cahen C., Roberts I., Theillet C., Caldas C., Edwards P.A.W.
Br. J. Cancer 83:1309-1317(2000).
Aberrations of chromosome 8 in 16 breast cancer cell lines by comparative genomic hybridization, fluorescence in situ hybridization, and spectral karyotyping.
Isola J.J.
Cancer Genet. Cytogenet. 126:1-7(2001).
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Edwards P.A.W., Chaffanet M.
Genes Chromosomes Cancer 37:333-345(2003).
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Edwards P.A.W., Caldas C.
Carcinogenesis 26:923-930(2005).
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.
Cancer Res. 66:41-45(2006).
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.
Breast Cancer Res. Treat. 99:97-101(2006).
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
Cancer Cell 10:515-527(2006).
High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization.
Ringner M., Hoglund M., Borg A.
Genes Chromosomes Cancer 46:543-558(2007).
The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression.
Petersen O.W., Gray J.W., Bissell M.J.
Mol. Oncol. 1:84-96(2007).
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
Pollack J.R.
PLoS ONE 4:E6146-E6146(2009).
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.
Breast Cancer Res. Treat. 121:53-64(2010).
Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.
Yamamoto S., Oka M., Hirano T., Sasaki K.
BMC Cancer 10:15.1-15.10(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Rottapel R., Neel B.G., Moffat J.
Cancer Discov. 2:172-189(2012).
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Martens J.W.M.
Breast Cancer Res. 15:R33.1-R33.17(2013).
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
McCormick F., Gray J.W.
Cancer Cell 24:450-465(2013).
Modeling precision treatment of breast cancer.";
Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.
Genome Biol. 14:R110.1-R110.14(2013).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
OncoImmunology 3:e954893.1-e954893.12(2014).